{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,22]],"date-time":"2026-10-22T22:59:58Z","timestamp":1792709998613,"version":"4.5.0"},"reference-count":39,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2016,9,29]],"date-time":"2016-09-29T00:00:00Z","timestamp":1475107200000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Endocrine"],"published-print":{"date-parts":[[2017,1]]},"DOI":"10.1007\/s12020-016-1115-2","type":"journal-article","created":{"date-parts":[[2016,9,29]],"date-time":"2016-09-29T10:39:57Z","timestamp":1475145597000},"page":"223-230","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":46,"title":["10-year follow-up study comparing primary medical vs. surgical therapy in women with prolactinomas"],"prefix":"10.1007","volume":"55","author":[{"given":"Lukas","family":"Andereggen","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Janine","family":"Frey","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Robert H.","family":"Andres","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marwan","family":"El-Koussy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J\u00fcrgen","family":"Beck","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rolf W.","family":"Seiler","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Emanuel","family":"Christ","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2016,9,29]]},"reference":[{"key":"1115_CR1","doi-asserted-by":"crossref","first-page":"1369","DOI":"10.3171\/2010.11.JNS101369","volume":"114","author":"MC Oh","year":"2011","unstructured":"M.C. Oh, M.K. Aghi, Dopamine agonist-resistant prolactinomas. J. Neurosurg. 114, 1369\u20131379 (2011)","journal-title":"J. Neurosurg."},{"key":"1115_CR2","doi-asserted-by":"crossref","first-page":"4721","DOI":"10.1210\/jc.2007-2758","volume":"93","author":"M Ono","year":"2008","unstructured":"M. Ono, N. Miki, T. Kawamata et al., Prospective study of high-dose cabergoline treatment of prolactinomas in 150 patients. J. Clin. Endocrinol. Metab. 93, 4721\u20134727 (2008)","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"1115_CR3","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1111\/cen.12418","volume":"81","author":"AI Green","year":"2014","unstructured":"A.I. Green, M. Sherlock, P.M. Stewart, N.J. Gittoes, A.A. Toogood, Extensive experience in the management of macroprolactinomas. Clin. Endocrinol. 81, 85\u201392 (2014)","journal-title":"Clin. Endocrinol."},{"key":"1115_CR4","doi-asserted-by":"crossref","first-page":"222","DOI":"10.1007\/s11102-010-0283-y","volume":"14","author":"M Babey","year":"2011","unstructured":"M. Babey, R. Sahli, I. Vajtai, R.H. Andres, R.W. Seiler, Pituitary surgery for small prolactinomas as an alternative to treatment with dopamine agonists. Pituitary 14, 222\u2013230 (2011)","journal-title":"Pituitary"},{"key":"1115_CR5","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1530\/EJE-07-0248","volume":"158","author":"J Kreutzer","year":"2008","unstructured":"J. Kreutzer, R. Buslei, H. Wallaschofski et al., Operative treatment of prolactinomas: indications and results in a current consecutive series of 212 patients. Eur. J. Endocrinol. 158, 11\u201318 (2008)","journal-title":"Eur. J. Endocrinol."},{"key":"1115_CR6","doi-asserted-by":"crossref","first-page":"331","DOI":"10.1016\/j.wneu.2012.06.024","volume":"79","author":"M Loyo-Varela","year":"2013","unstructured":"M. Loyo-Varela, T. Herrada-Pineda, F. Revilla-Pacheco, S. Manrique-Guzman, Pituitary tumor surgery: review of 3004 cases. World Neurosurg. 79, 331\u2013336 (2013)","journal-title":"World Neurosurg."},{"key":"1115_CR7","doi-asserted-by":"crossref","first-page":"779","DOI":"10.1530\/EJE-11-1000","volume":"166","author":"V Primeau","year":"2012","unstructured":"V. Primeau, C. Raftopoulos, D. Maiter, Outcomes of transsphenoidal surgery in prolactinomas: improvement of hormonal control in dopamine agonist-resistant patients. Eur. J. Endocrinol. 166, 779\u2013786 (2012)","journal-title":"Eur. J. Endocrinol."},{"key":"1115_CR8","doi-asserted-by":"crossref","first-page":"499","DOI":"10.1530\/EJE-10-0961","volume":"164","author":"X Qu","year":"2011","unstructured":"X. Qu, M. Wang, G. Wang et al., Surgical outcomes and prognostic factors of transsphenoidal surgery for prolactinoma in men: a single-center experience with 87 consecutive cases. Eur. J. Endocrinol. 164, 499\u2013504 (2011)","journal-title":"Eur. J. Endocrinol."},{"key":"1115_CR9","doi-asserted-by":"crossref","first-page":"1785","DOI":"10.1016\/j.jocn.2015.06.001","volume":"22","author":"TR Smith","year":"2015","unstructured":"T.R. Smith, M.M. Hulou, K.T. Huang et al., Current indications for the surgical treatment of prolactinomas. J. Clin. Neurosci. 22, 1785\u20131791 (2015)","journal-title":"J. Clin. Neurosci."},{"key":"1115_CR10","doi-asserted-by":"crossref","first-page":"495","DOI":"10.1007\/s00234-011-0915-6","volume":"54","author":"L Andereggen","year":"2012","unstructured":"L. Andereggen, G. Schroth, J. Gralla et al., Selective inferior petrosal sinus sampling without venous outflow diversion in the detection of a pituitary adenoma in Cushing\u2019s syndrome. Neuroradiology 54, 495\u2013503 (2012)","journal-title":"Neuroradiology"},{"key":"1115_CR11","doi-asserted-by":"crossref","first-page":"463","DOI":"10.1148\/radiology.215.2.r00ap18463","volume":"215","author":"JP Cottier","year":"2000","unstructured":"J.P. Cottier, C. Destrieux, L. Brunereau et al., Cavernous sinus invasion by pituitary adenoma: MR imaging. Radiology 215, 463\u2013469 (2000)","journal-title":"Radiology"},{"key":"1115_CR12","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1007\/s11102-007-0072-4","volume":"11","author":"ZB Wu","year":"2008","unstructured":"Z.B. Wu, Z.P. Su, J.S. Wu, W.M. Zheng, Q.C. Zhuge, M. Zhong, Five years follow-up of invasive prolactinomas with special reference to the control of cavernous sinus invasion. Pituitary 11, 63\u201370 (2008)","journal-title":"Pituitary"},{"key":"1115_CR13","doi-asserted-by":"crossref","first-page":"762","DOI":"10.3171\/jns.2000.93.5.0762","volume":"93","author":"RW Seiler","year":"2000","unstructured":"R.W. Seiler, L. Mariani, Sellar reconstruction with resorbable vicryl patches, gelatin foam, and fibrin glue in transsphenoidal surgery: a 10-year experience with 376 patients. J. Neurosurg. 93, 762\u2013765 (2000)","journal-title":"J. Neurosurg."},{"key":"1115_CR14","doi-asserted-by":"crossref","first-page":"298","DOI":"10.1038\/ncpendmet0162","volume":"2","author":"JA Wass","year":"2006","unstructured":"J.A. Wass, When to discontinue treatment of prolactinoma? Nat. Clin. Pract. Endocrinol. Metab. 2, 298\u2013299 (2006)","journal-title":"Nat. Clin. Pract. Endocrinol. Metab."},{"key":"1115_CR15","doi-asserted-by":"crossref","first-page":"2023","DOI":"10.1056\/NEJMoa022657","volume":"349","author":"A Colao","year":"2003","unstructured":"A. Colao, A. Di Sarno, P. Cappabianca, C. Di Somma, R. Pivonello, G. Lombardi, Withdrawal of long-term cabergoline therapy for tumoral and nontumoral hyperprolactinemia. N. Engl. J. Med. 349, 2023\u20132033 (2003)","journal-title":"N. Engl. J. Med."},{"key":"1115_CR16","doi-asserted-by":"crossref","first-page":"3180","DOI":"10.1210\/jcem.87.7.8645","volume":"87","author":"M Losa","year":"2002","unstructured":"M. Losa, P. Mortini, R. Barzaghi, L. Gioia, M. Giovanelli, Surgical treatment of prolactin-secreting pituitary adenomas: early results and long-term outcome. J. Clin. Endocrinol. Metab. 87, 3180\u20133186 (2002)","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"1115_CR17","doi-asserted-by":"crossref","first-page":"1708","DOI":"10.1210\/jc.2009-1191","volume":"95","author":"G Raverot","year":"2010","unstructured":"G. Raverot, A. Wierinckx, E. Dantony et al., Prognostic factors in prolactin pituitary tumors: clinical, histological, and molecular data from a series of 94 patients with a long postoperative follow-up. J. Clin. Endocrinol. Metab. 95, 1708\u20131716 (2010)","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"1115_CR18","doi-asserted-by":"crossref","unstructured":"Bloomgarden E., Molitch M.E. Surgical treatment of prolactinomas: cons. Endocrine 47, 730\u2013733 (2014)","DOI":"10.1007\/s12020-014-0369-9"},{"key":"1115_CR19","doi-asserted-by":"crossref","first-page":"421","DOI":"10.1007\/s11060-013-1270-8","volume":"117","author":"ME Molitch","year":"2014","unstructured":"M.E. Molitch, Management of medically refractory prolactinoma. J. Neuro-oncol. 117, 421\u2013428 (2014)","journal-title":"J. Neuro-oncol."},{"key":"1115_CR20","doi-asserted-by":"crossref","first-page":"698","DOI":"10.1210\/jcem-60-4-698","volume":"60","author":"ME Molitch","year":"1985","unstructured":"M.E. Molitch, R.L. Elton, R.E. Blackwell et al., Bromocriptine as primary therapy for prolactin-secreting macroadenomas: results of a prospective multicenter study. J. Clin. Endocrinol. Metab. 60, 698\u2013705 (1985)","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"1115_CR21","doi-asserted-by":"crossref","first-page":"904","DOI":"10.1056\/NEJM199410063311403","volume":"331","author":"J Webster","year":"1994","unstructured":"J. Webster, G. Piscitelli, A. Polli, C.I. Ferrari, I. Ismail, M.F. Scanlon, A comparison of cabergoline and bromocriptine in the treatment of hyperprolactinemic amenorrhea. Cabergoline Comparative Study Group. N. Engl. J. Med. 331, 904\u2013909 (1994)","journal-title":"N. Engl. J. Med."},{"key":"1115_CR22","doi-asserted-by":"crossref","first-page":"863","DOI":"10.1111\/cen.12375","volume":"80","author":"I Bancos","year":"2014","unstructured":"I. Bancos, M.R. Nannenga, J.M. Bostwick, M.H. Silber, D. Erickson, T.B. Nippoldt, Impulse control disorders in patients with dopamine agonist-treated prolactinomas and nonfunctioning pituitary adenomas: a case-control study. Clin. Endocrinol. 80, 863\u2013868 (2014)","journal-title":"Clin. Endocrinol."},{"key":"1115_CR23","doi-asserted-by":"crossref","first-page":"90","DOI":"10.1210\/jc.2013-2254","volume":"99","author":"WM Drake","year":"2014","unstructured":"W.M. Drake, C.E. Stiles, T.A. Howlett, A.A. Toogood, J.S. Bevan, R.P. Steeds, A cross-sectional study of the prevalence of cardiac valvular abnormalities in hyperprolactinemic patients treated with ergot-derived dopamine agonists. J. Clin. Endocrinol. Metab. 99, 90\u201396 (2014)","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"1115_CR24","doi-asserted-by":"crossref","first-page":"921","DOI":"10.1515\/JPEM.2005.18.9.921","volume":"18","author":"F Galluzzi","year":"2005","unstructured":"F. Galluzzi, R. Salti, S. Stagi, F. La Cauza, F. Chiarelli, Reversible weight gain and prolactin levels--long-term follow-up in childhood. J. Pediatr. Endocrinol. Metab. 18, 921\u2013924 (2005)","journal-title":"J. Pediatr. Endocrinol. Metab."},{"key":"1115_CR25","doi-asserted-by":"crossref","first-page":"6","DOI":"10.1056\/NEJMp068265","volume":"356","author":"BL Roth","year":"2007","unstructured":"B.L. Roth, Drugs and valvular heart disease. N. Engl. J. Med. 356, 6\u20139 (2007)","journal-title":"N. Engl. J. Med."},{"key":"1115_CR26","doi-asserted-by":"crossref","first-page":"2518","DOI":"10.1210\/jcem.84.7.5810","volume":"84","author":"J Verhelst","year":"1999","unstructured":"J. Verhelst, R. Abs, D. Maiter et al., Cabergoline in the treatment of hyperprolactinemia: a study in 455 patients. J. Clin. Endocrinol. Metab. 84, 2518\u20132522 (1999)","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"1115_CR27","doi-asserted-by":"crossref","first-page":"2428","DOI":"10.1210\/jc.2008-2103","volume":"94","author":"J Kharlip","year":"2009","unstructured":"J. Kharlip, R. Salvatori, G. Yenokyan, G.S. Wand, Recurrence of hyperprolactinemia after withdrawal of long-term cabergoline therapy. J. Clin. Endocrinol. Metab. 94, 2428\u20132436 (2009)","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"1115_CR28","doi-asserted-by":"crossref","first-page":"820","DOI":"10.1007\/s11102-015-0658-1","volume":"18","author":"O Cohen-Inbar","year":"2015","unstructured":"O. Cohen-Inbar, Z. Xu, D. Schlesinger, M.L. Vance, J.P. Sheehan, Gamma knife radiosurgery for medically and surgically refractory prolactinomas: long-term results. Pituitary 18, 820\u2013830 (2015)","journal-title":"Pituitary"},{"key":"1115_CR29","doi-asserted-by":"crossref","first-page":"68","DOI":"10.1007\/s11102-010-0261-4","volume":"14","author":"M Menucci","year":"2011","unstructured":"M. Menucci, A. Quinones-Hinojosa, P. Burger, R. Salvatori, Effect of dopaminergic drug treatment on surgical findings in prolactinomas. Pituitary 14, 68\u201374 (2011)","journal-title":"Pituitary"},{"key":"1115_CR30","doi-asserted-by":"crossref","first-page":"906","DOI":"10.1016\/S2213-8587(14)70212-8","volume":"3","author":"C Caputo","year":"2015","unstructured":"C. Caputo, D. Prior, W.J. Inder, The need for annual echocardiography to detect cabergoline-associated valvulopathy in patients with prolactinoma: a systematic review and additional clinical data. Lancet Diabetes Endocrinol. 3, 906\u2013913 (2015)","journal-title":"Lancet Diabetes Endocrinol."},{"key":"1115_CR31","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1530\/EJE-12-0121","volume":"167","author":"A Elenkova","year":"2012","unstructured":"A. Elenkova, R. Shabani, K. Kalinov, S. Zacharieva, Increased prevalence of subclinical cardiac valve fibrosis in patients with prolactinomas on long-term bromocriptine and cabergoline treatment. Eur. J. Endocrinol. 167, 17\u201325 (2012)","journal-title":"Eur. J. Endocrinol."},{"key":"1115_CR32","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1111\/j.1365-2265.2011.04326.x","volume":"77","author":"V Delgado","year":"2012","unstructured":"V. Delgado, N.R. Biermasz, S.W. van Thiel et al., Changes in heart valve structure and function in patients treated with dopamine agonists for prolactinomas, a 2-year follow-up study. Clin. Endocrinol. 77, 99\u2013105 (2012)","journal-title":"Clin. Endocrinol."},{"key":"1115_CR33","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1056\/NEJMoa062222","volume":"356","author":"R Schade","year":"2007","unstructured":"R. Schade, F. Andersohn, S. Suissa, W. Haverkamp, E. Garbe, Dopamine agonists and the risk of cardiac-valve regurgitation. N. Engl. J. Med. 356, 29\u201338 (2007)","journal-title":"N. Engl. J. Med."},{"key":"1115_CR34","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1007\/s11102-011-0303-6","volume":"15","author":"P Anagnostis","year":"2012","unstructured":"P. Anagnostis, F. Adamidou, S.A. Polyzos, Z. Efstathiadou, E. Karathanassi, M. Kita, Long term follow-up of patients with prolactinomas and outcome of dopamine agonist withdrawal: a single center experience. Pituitary 15, 25\u201329 (2012)","journal-title":"Pituitary"},{"key":"1115_CR35","first-page":"254","volume":"136","author":"C Schmid","year":"2006","unstructured":"C. Schmid, D.L. Goede, R.S. Hauser, M. Brandle, Increased prevalence of high Body Mass Index in patients presenting with pituitary tumours: severe obesity in patients with macroprolactinoma. Swiss Med. Wkly. 136, 254\u2013258 (2006)","journal-title":"Swiss Med. Wkly."},{"key":"1115_CR36","doi-asserted-by":"crossref","first-page":"800","DOI":"10.1038\/oby.2010.150","volume":"19","author":"CM Santos Silva dos","year":"2011","unstructured":"C.M. dos Santos Silva, F.R. Barbosa, G.A. Lima et al., BMI and metabolic profile in patients with prolactinoma before and after treatment with dopamine agonists. Obesity 19, 800\u2013805 (2011)","journal-title":"Obesity"},{"key":"1115_CR37","doi-asserted-by":"crossref","first-page":"562","DOI":"10.1046\/j.1365-2265.2002.01510.x","volume":"56","author":"R Yermus","year":"2002","unstructured":"R. Yermus, S. Ezzat, Does normalization of prolactin levels result in weight loss in patients with prolactin secreting pituitary adenomas? Clin. Endocrinol. 56, 562 (2002)","journal-title":"Clin. Endocrinol."},{"key":"1115_CR38","doi-asserted-by":"crossref","first-page":"547","DOI":"10.1046\/j.1365-2265.1998.00403.x","volume":"48","author":"Y Greenman","year":"1998","unstructured":"Y. Greenman, K. Tordjman, N. Stern, Increased body weight associated with prolactin secreting pituitary adenomas: weight loss with normalization of prolactin levels. Clin. Endocrinol. 48, 547\u2013553 (1998)","journal-title":"Clin. Endocrinol."},{"key":"1115_CR39","doi-asserted-by":"crossref","first-page":"845","DOI":"10.1111\/cen.12204","volume":"79","author":"A Ciresi","year":"2013","unstructured":"A. Ciresi, M.C. Amato, V. Guarnotta, F. Lo Castro, C. Giordano, Higher doses of cabergoline further improve metabolic parameters in patients with prolactinoma regardless of the degree of reduction in prolactin levels. Clin. Endocrinol. 79, 845\u2013852 (2013)","journal-title":"Clin. Endocrinol."}],"container-title":["Endocrine"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s12020-016-1115-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s12020-016-1115-2\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s12020-016-1115-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2017,6,24]],"date-time":"2017-06-24T23:57:24Z","timestamp":1498348644000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s12020-016-1115-2"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,9,29]]},"references-count":39,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2017,1]]}},"alternative-id":["1115"],"URL":"https:\/\/doi.org\/10.1007\/s12020-016-1115-2","relation":{},"ISSN":["1355-008X","1559-0100"],"issn-type":[{"value":"1355-008X","type":"print"},{"value":"1559-0100","type":"electronic"}],"subject":[],"published":{"date-parts":[[2016,9,29]]}}}